In Stafford, Texas on December 22, 2025, Greenwich LifeSciences, Inc. (Nasdaq: GLSI) shared updates on their Phase III clinical trial, FLAMINGO-01. The focus of the trial is GLSI-100, an immunotherapy designed to prevent the recurrence of breast cancer. The Company revealed information regarding the progress of FLAMINGO-01 and also discussed its corporate strategy going forward.